Verimatrix and Velocix Team Up to Fight CDN Piracy
10.9.2025 18:45:00 EEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced a strategic collaboration with Velocix, the market’s premier carrier-grade CDN software provider, to help streaming providers combat piracy, boost paid video subscriptions, and cut CDN costs. This joint initiative provides streaming providers with the means to detect, deny, and prevent unsanctioned usage of CDN capacity by third parties.
CDN leeching, where unauthorized users consume content directly from the network without paying for it, is a critical and costly challenge for video service providers. Verimatrix Streamkeeper™ Counterspy protects the client side, ensuring only legitimate users can access content, by providing string app authentication, protecting content keys, and safeguarding the token exchange. Velocix’s Carrier-Grade CDN and Video Analytics Platform bring powerful server-side features, including advanced tokenization schemes, rate throttling, token revocation, and AI-powered anomaly detection. Together, the companies combined strengths across the delivery chain provide a means to stop stream piracy, safeguard premium content, and reduce delivery costs. Operators can also grow video subscriptions by enforcing paid relationships and improving the experience for legitimate subscribers by unlocking pirated bandwidth on the CDN for paid users. CDN demands can be reduced by 30% or more during peak usage periods thanks to the elimination of illicit traffic.
“Collaborating with Velocix was a logical step for Verimatrix, as we have complementary technology and share a common goal of protecting streaming provider’s bottom line from the scourge of stream piracy,” said Carlo Stramaglia, head of Anti-Piracy Business at Verimatrix. “Streamkeeper Counterspy was designed to work hand-in-hand with CDNs, and Velocix is the ideal partner to showcase how we can turn piracy protection into a direct cost-saving and revenue-generating advantage for our customers and theirs.”
“CDN leeching is a critical concern for the streaming industry because the negative impacts to video businesses are big, real, and happening right now,” said Marco Rico, Head of Products at Velocix. “Our alliance with Verimatrix, enables us to combine our considerable experience to offer operators a clear path to combat stream theft to both reduce costs and drive higher returns, enabling them to run better, more profitable video businesses.”
This collaboration signals a major opportunity for broadcasters, pay-TV operators, and streaming providers seeking a holistic approach to tackling piracy and ensuring optimal business performance.
To learn more, watch the joint webinar, “Stop the Steal: Inside CDN Leeching & Piracy” on demand here or meet with the teams in person at IBC 2025, RAI Amsterdam, from September 12th-15th: Schedule a meeting with Verimatrix (Hall 1 – BS.20), or request a meeting with Velocix (Hall 5 – C.75).
About Velocix
Velocix is the world’s leading provider of carrier-grade video streaming, control plane, and analytics technology, powering exceptional entertainment experiences for the world’s largest operators. Its hybrid-cloud software solutions scale to support billions of viewing sessions every year, enabling operators to maximize efficiency, security, and monetization of their video services. Learn more at www.velocix.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909231415/en/
Contacts
Velocix Media Contact:
Jane Allan
jane.allan@velocix.com
Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
SEITOSEI.ACTIFIN
Michael Scholze
michael.scholze@seitosei-actifin.com
Verimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom